Rosiglitazone is associated with mortality in chronic hemodialysis patients

Journal of the American Society of Nephrology

Volumn 20, Issue 5, 2009, Pages 1094-1101

  Ramirez, Sylvia P B ^a   Albert, Justin M ^a   Blayney, Margaret J ^a   Tentori, Francesca ^a   Goodkin, David A ^a   Wolfe, Robert A ^a   Young, Eric W ^a   Bailie, George R ^b   Pisoni, Ronald L ^a   Port, Friedrich K ^a,c  

^a UNIVERSITY OF MICHIGAN   (United States)

^b ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^c ARBOR RESEARCH COLLABORATIVE FOR HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; ROSIGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; FOLLOW UP; HEART INFARCTION; HEMODIALYSIS PATIENT; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; AGED; CHRONIC KIDNEY FAILURE; DIABETIC ANGIOPATHY; DIABETIC NEPHROPATHY; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; RENAL REPLACEMENT THERAPY; STATISTICS;

AGED; CARDIOVASCULAR DISEASES; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; FEMALE; HOSPITALIZATION; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RENAL DIALYSIS; THIAZOLIDINEDIONES;

EID: 65649089128     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2008060579     Document Type: Article

References (34)

1. Masoudi FA, Wang Y, Inzucchi SE, Setaro JF, Havranek EP, Foody JM, Krumholz HM: Metformin and thiazolidinedione use in Medicare patients with heart failure. JAMA 290: 81-85, 2003 (Pubitemid 37432869)
2. Nissen SE, Wolski K: Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356: 2457-2499, 2007
3. Singh S, Loke YK, Furberg CD: Long-term risk of cardiovascular events with rosiglitazone: A meta-analysis. JAMA 10: 1189-1195, 2007 (Pubitemid 47403105)
4. Raji A, Seely EW, Bekins SA, Williams GH, Simonson DC: Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients. Diabetes Care 26: 172-178, 2003 (Pubitemid 36929012)
5. Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI: Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 106: 679-684, 2002
6. Kidney Disease Outcomes Quality Initiative Workgroup: KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis 49[Suppl 2]:S12-S154, 2007
7. US Renal Data System: USRDS 2006 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, Bethesda, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2006
8. Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, Le Winter M, Porte D, Semenkovich CF, Smith S, Young LH, Kahn R, American Heart Association, American Diabetes Association: Thiazolidinedione use, fluid retention and congestive heart failure: A consensus statement from the American Heart Association and the American Diabetes Association. Circulation 108: 2941-2948, 2003 (Pubitemid 37517824)
9. Kidney Disease Outcomes Quality Initiative Workgroup: K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis 45[Suppl 3]: S1-S153, 2005
10. Cowie CC, Port FK, Wolfe RA, Savage PJ, Moll PP, Hawthorne VM: Disparity in incidence of diabetic end-stage renal disease by race and diabetic type. N Engl J Med 321: 1074-1079, 1989
11. The DREAM (Diabetes Reduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators: Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: A randomized controlled trial. Lancet 368: 1096-1105, 2006
12. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B, Viberti G, ADOPT Study Group: Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355: 2427-2443, 2006
13. Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJ, RECORD Study Group: Rosiglitazone evaluated for cardiovascular outcomes: An interim analysis. N Engl J Med 357: 28-38, 2007 (Pubitemid 47026732)
14. Goldberg RB: Impact of thiazolidinediones on serum lipoprotein levels. Curr Atheros Rep 8: 397-404, 2006
15. Lindenfeld J, Masoudi FA: Fluid retention with thiazolidinediones: Does the mechanism influence the outcome? J Am Coll Cardiol 49: 1705-1707, 2007
16. Hall JM, McDonnell DP: The molecular mechanisms underlying the pro-inflammatory actions of thiazolidinediones in human macrophages. Mol Endocrinol 21: 1756-1768, 2007
17. Desmet C, Warzee B, Gosset P, Melotte D, Rongvaux A, Gillet L, Fievez L, Seumois G, Vanderplasschen A, Staels B, Lekeux P, Bureau F: Pro-inflammatory properties for thiazolidinediones. Biochem Pharmacol 69: 255-265, 2005 (Pubitemid 41556572)
18. Tan NS, Michalik L, Noy N, Yasmin R, Pacot C, Heim M, Fluhmann B, Desvergne B, Wahli W: Critical roles of PPAR beta/delta in keratinocyte response to inflammation. Genes Dev 15: 3263-3277, 2001 (Pubitemid 34008192)
19. Krane V, Drechsler C, Wanner C: Dyslipidemia, inflammation and dialysis outcomes: What we know now. Curr Opin Nephrol Hypertens 15: 566-570, 2006 (Pubitemid 44607425)
20. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE: Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis of randomized trials. JAMA 298: 1180-1188, 2007 (Pubitemid 47403104)
21. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefebvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Koranyi L, Laakso M, Mokan M, Norkus A, Piragas V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J, PROactive investigators: Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial in macroVascular Events): A randomised controlled trial. Lancet 366: 1279-1289, 2005 (Pubitemid 41416583)
22. Erdmann E, Dormandy JA, Charbonnel B, Massi-Benedetti M, Moules IK, Skene AM, PROactive Investigators: The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: Results from the PROactive (PROactive 05) Study. J Am Coll Cardiol 49: 1772-1780, 2007 (Pubitemid 46629127)
23. Hanefield M, Marx N, Pfutzner A, Baurecht W, Lubben G, Karagiannis E, Stier U, Forst T: Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity-CRP: The PIOSTAT study. J Am Coll Cardiol 49: 290-297, 2007 (Pubitemid 46110954)
24. Pfutzner A, Marx N, Lubben G, Langenfeld M, Walcher D, Konrad T, Forst T: Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: Results from the Pioneer Study. J Am Coll Cardiol 45: 1925-1931, 2005 (Pubitemid 40814110)
25. Lawrence JM, Reid J, Taylor GJ, Stirling C, Reckless JP: Favorable effects of pioglitazone and metformin compared with gliclazide on lipoprotein subfractions in overweight patients with early type 2 diabetes. Diabetes Care 27: 41-46, 2004 (Pubitemid 38196707)
26. Nissen SE, Nicholls SJ, Wolski K, Nesto R, Kupfer S, Perez A, Jure H, DeLarochellière R, Staniloae CS, Mayromatis K, Saw J, Hu B, Lincoff AM, Tuzcu EM, PERISCOPE Investigators: Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: The PERISCOPE randomized controlled trial. JAMA 299: 1561-1573, 2008
27. Hernán MA, Robins JM: Instruments for causal inference: An epidemiologist's dream. Epidemiology 17: 360-372, 2006
28. Brookhart MA, Wang PS, Solomon DH, Schneeweiss S: Evaluating short-term drug effects using a physician-specific prescribing preference as an instrumental variable. Epidemiology 17: 268-275, 2006
29. Johnston SC: Combining ecological and individual variables to reduce confounding by indication: Case study - Subarachnoid hemorrhage treatment. J Clin Epidemiol 53: 1236-1241, 2000
30. Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Dargie H, Komajda M, Gubb J, Biswas N, Jones NP: Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): Study design and protocol. Diabetologia 48: 1726-1735, 2005 (Pubitemid 41317825)
31. Young EW, Goodkin DA, Mapes DL, Port FK, Keen ML, Chen K, Maroni BL, Wolfe RA, Held PJ: The Dialysis Outcomes and Practice Patterns Study (DOPPS): An international hemodialysis study. Kidney Int 57[Suppl 74]: S74-S81, 2000 (Pubitemid 43309175)
32. Pisoni RL, Gillespie BW, Dickinson DM, Chen K, Kutner MH, Wolfe RA: The Dialysis Outcomes and Practice Patterns Study (DOPPS): Design, data elements, and methodology. Am J Kidney Dis 44[Suppl 2]: 7-15, 2004 (Pubitemid 39369935)
33. Allison PD: Missing Data, Thousand Oaks, CA, Sage University Press, 2002, pp 9-11
34. Klein J, Moeschberger M: Survival Analysis Techniques for Censored and Truncated Data, New York, Springer, 1997, pp 416-418